| Date | Title | Description |
| 18.05.2022 | adMare Appoints Dr. Christine Allen as Vice-President, Ecosystem Development | Toronto May 18, 2022 – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong life sciences ecosystem thro... |
| 10.05.2022 | adMare BioInnovations joins a $42m Series A financing in Domain Therapeutics | Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, annou... |
| 03.05.2022 | adMare BioInnovations Collaborates with Accelerator Company, Molecular Forecaster Inc. on Computational Approaches to Drug Discovery | MONTREAL, QUEBEC, April 5, 2022 – Molecular Forecaster Inc. (MFI) is excited to announce a partnership with
adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D
programs in adMare’s pipel... |
| 02.05.2022 | adMare Portfolio Company, Zucara Therapeutics Secures Additional Funding for the Development of ZT-01 | Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has received s... |
| 15.04.2022 | Read the newest issue of the adMare Quarterly newsletter – April 12, 2022 | adMare Quarterly It has been a busy few months at adMare! From a transformative investment of $92M recently announced by the Minister of Innovation, Science and Industry at our Innovation Centre in Vancouver, to our new partnership with adM... |
| 08.04.2022 | Building Canada’s Life Sciences Industry on a Strong Foundation of Canadian Talent | Labour shortages are hitting virtually every Canadian sector, from coffee shops to car manufacturing – and life sciences is no exception. But what is exceptional about our industry is its vital importance to Canada’s health security and eco... |
| 30.03.2022 | Government of Canada Invests $92 million in adMare to help translate health research into innovative new therapies in Canada | GOVERNMENT OF CANADA RELEASE
Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development
March 30, 2022 – Vancouver, British Columbia – Innovation, Science and Economic ... |
| 16.03.2022 | Listen to adMare’s President & CEO, Gordon C. McCauley on CGEn’s New Podcast, Synapsis | adMare’s President & CEO, Gordon C. McCauley speaks with Dr. Naveed Aziz on the first episode of CGEn’s new podcast, Synapsis, about the health sciences sector and what can be done to leverage Canada’s competitive advantages on the glob... |
| 14.03.2022 | Join Us For adMare’s Global Leaders Webinar Featuring Dr. Robert Langer April 19, 2022 | adMare Global Leaders Webinar
From Lab bench to clinic: How to solve global health challenges by developing new therapies through innovation and founding new companies
Featuring Dr. Robert Langer
adMare’s Global Leaders webinar series is pl... |
| 11.03.2022 | adMare supports Ukraine; Responds to Ministers Champagne and Duclos | Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health issued a statement on additional measures in response to Vladimir Putin’s unjustifiable... |
| 08.03.2022 | Join Us For adMare’s Lunch & Learn: Building Talent with Amplitude Ventures March 17, 2022 | The Amplitude Fellowship – Training the next generation of life science entrepreneurs
Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor? Do you want to stay rooted in health and life science while explorin... |
| 14.02.2022 | adMare Portfolio Company, Find Therapeutics, Appoints Dr. Philippe Douville as Chief Executive Officer | MONTREAL, Feb. 14, 2022 – Find Therapeutics Inc. (‘Find’) is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer.
Dr. Douville brings to Find 25 years of sector... |
| 08.02.2022 | adMare Portfolio Company, Zucara Therapeutics Announces Publication of Preclinical Study | Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that the peer-rev... |
| 17.01.2022 | Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update | MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder ... |
| 13.01.2022 | adMare Portfolio Company NIMIUM Therapeutics’ Research Breakthrough Shows Promise To Maintain Good Health As We Age | MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate Phosphatase (... |
| 12.01.2022 | adMare Portfolio Company Neurasic Therapeutics Receives New Grant to Advance Non-Opioid Pain Treatment | Montréal – Québec – January 12th, 2022 –CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative and the Louise and Alan Ed... |
| 16.12.2021 | Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations | Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases.
Toronto, Ontario, Canada [December 16, 2021] Speci... |
| 15.12.2021 | Join Us for adMare’s Industry Builder Webinar Featuring Dr. Michel Bouvier – Jan. 17, 2022
Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better dr... | Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs?
Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier is a distinguished professor of... |
| 18.11.2021 | adMare BioInnovations Announces Successful Applicants to 2021-2022 Executive Institute | Vancouver, BC and Montreal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to ... |
| 15.11.2021 | adMare BioInnovations and uOttawa Work Together to Translate University Research into Strong New Canadian Life Science Companies | Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the building of life science companies and talent at the Univ... |
| 09.11.2021 | adMare BioInnovations and CASTL Partner to Build Canada’s Biomanufacturing Talent | Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Cana... |
| 02.11.2021 | adMare BioInnovations and District 3 Innovation partner to provide science-based Canadian startups more cohesive support to grow into industry leaders | MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry from sea to sea, are pleas... |
| 21.10.2021 | adMare’s President & CEO Gordon C. McCauley is Appointed to BIOVECTRA Board of Directors | Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its... |
| 28.09.2021 | adMare’s Accelerate Quebec Company, Molecular Forecaster, Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships | The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease
Montreal, Quebe... |
| 17.09.2021 | adMare Portfolio Company, Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker | MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 20... |
| 29.07.2021 | Please wait while your request is being verified... | - |
| 03.06.2021 | CPDC/adMare Radiopharmaceutical Initiative (CARI): New blog post – Q&A session with our experts | Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in healthcare and in the life scienc... |
| 17.05.2021 | adMare and AazeinTx Inc Sign Global Exclusive Agreement | adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment.
Under the agreement, AazeinTx has acquired all rights to NEO6860, a clinical-stage ... |
| 12.04.2021 | adMare BioInnovations launches Canada’s first & only digital life sciences community | In our COVID world, we all need to get creative in building new ways to safely and effectively come together. The pandemic is showing us that Canada needs strong life sciences industry leaders and a dynamic and well-connected national ecosy... |
| 10.02.2021 | Soundbite Medical Solutions Announces Health Canada Approval for SoundBite® Crossing System ‐ Peripheral (14P) | Soundbite announces Health Canada Approval for SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire (14P).
The SCS-P (14P) is intended for the treatment of patients suffering from peripheral artery disease (PAD) with h... |
| 10.02.2021 | Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada | Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, se... |
| 27.01.2021 | New Canadian Pharmaceutical Company Brings Novel Cancer Therapies To Market | FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment secured, ... |
| 11.12.2020 | Join us in the 50 – 30 Challenge | adMare is proud to be an early adopter of the Government’s 50 – 30 Challenge to accelerate diversity and inclusion in our workforce at the senior leadership level.
To build a stronger life sciences industry across Canada, we know that one o... |
| 10.12.2020 | adMare BioInnovations Welcomes the First Quebec Start-Ups in its Accelerate Program | adMare today unveiled the six companies selected under its new acceleration program supported by the Quebec Government and the City of Montreal.
Montréal, QC – December 10, 2020 – adMare BioInnovations, Canada’s global life sciences venture... |
| 02.12.2020 | Event: Announcement of the Companies Selected Under adMare Accelerate Program | adMare BioInnovations, Canada’s global life sciences venture, invites you to join us on Thursday, December 10 at 11:00 am (EST), for the unveiling of the six exciting start-ups selected for our new Accelerate Program.
Join us to discover th... |
| 26.11.2020 | Radiopharmaceuticals: a new class of drugs for cancer patients, and a new road for Canada to lead global life sciences | The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada is already a global leader in radioisotope-based hea... |
| 26.11.2020 | adMare’s cross-Canada virtual roadtrip – British Columbia Stop | COVID-19 may be keeping us from getting on planes and meeting in person, but it’s not stopping us from continuing to build Canada’s life sciences industry from sea to sea, as we continue our cross-Canada virtual roadtrip.
On December 1st at... |
| 16.11.2020 | Developing Canada’s Next Generation of Commercial Life Scientists | adMare Academy Responds to Pandemic with New Pan-Canadian
BioInnovation Scientist Program
November 16, 2020: adMare BioInnovations, Canada’s global life sciences venture, is proud to announce the launch of its new BioInnovation Scientist (B... |
| 02.11.2020 | Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes | – ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding –
Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily... |
| 15.10.2020 | Didier Leconte Elected Chair of adMare Board | Vancouver and Montréal, Canada – October 15, 2020: adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the election of Mr. Didier Leconte, Vice President, Investments – Life Sciences and Funds Management wit... |
| 17.09.2020 | Unleashing Canada’s Radiopharmaceutical Excellence | New Pan-Canadian Partnership Looks to Commercialize the Country’s Most Promising Radiopharmaceutical Innovations
September 17, 2020: The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are please... |
| 14.09.2020 | Global Pandemic Drives Unprecedented Need to Grow Canada’s Life Science Leadership | adMare Academy Announces New Executive Institute Cohort
Vancouver and Montreal, Canada – September 14, 2020: After receiving a record number of applications from across Canada, adMare BioInnovations (adMare) is pleased to announce the succe... |
| 08.09.2020 | adMare is pleased to increase our investment in Inversago Pharma alongside leading life sciences investors and be a part of building this exceptional Canadian company developing innovative therapies | Inversago Pharma closes US$35M Series B financing round and expands Board of Directors
Vancouver and Montreal, Canada – September 8, 2020: Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today anno... |
| 16.07.2020 | CDL Health and adMare BioInnovations partner to accelerate the commercialization of health innovations | Companies in CDL Health will benefit from adMare’s scientific and business expertise, infrastructure, and capital to drive health-related technologies to companies of scale.
Vancouver and Montreal, Canada – July 16, 2020: Creative Destructi... |
| 26.06.2020 | adMare BioInnovations Strengthens Leadership Team | June 26, 2020 – adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the appointment to its leadership team of Dr. Laura McIntosh as Venture Partner, Montreal, and Linda Downs as Vice President, Human Resourc... |
| 08.06.2020 | Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal | The new company raises initial capital to develop transmembrane peptides against GPCRs to address high unmet needs.
Montreal, Canada – June 8, 2020: CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and Pepti... |
| 04.06.2020 | New Company to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain | Montreal, Canada – June 4, 2020: adMare BioInnovations, Canada’s Global Life Sciences Venture, along with partners McGill University and AmorChem II Fund l.p., a leading early-stage venture capital fund, is advancing made-in-Canada research... |
| 21.05.2020 | adMare Academy Executive Institute – Developing Canada’s Life Sciences Leaders in a COVID World and Beyond | Applications Now Open for 2020-2021 Program
Vancouver, Canada: adMare BioInnovations, Canada’s global life sciences venture, is proud to open applications to its 2020-2021 Executive Institute – a 10-month, highly-focused executive developme... |
| 21.04.2020 | On the Cutting-Edge of the Fight Against the Pandemic | Variational AI Receives Support from the Digital Technology Supercluster for Repurposing of Drugs for COVID-19
Vancouver, British Columbia – Variational AI Inc. is pleased to announce a new project using their novel artificial intelligence ... |
| 31.03.2020 | Zucara Therapeutics, an adMare & TIAP Spin-off Company, Announces $21M Series A Financing | Toronto, Canada – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million ... |
| 26.03.2020 | adMare and BELLUS Health Close Transaction for Intellectual Property Rights to P2X3 Platform | Montreal, QC: As announced Wednesday by BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS”), adMare BioInnovations (“adMare”) and BELLUS have closed an agreement under which BELLUS has acquired full ownership of intellect... |
| 21.01.2020 | adMare Portfolio Company Receives FDA 510(k) Clearance | adMare BioInnovations Portfolio Company SoundBite Receives FDA 510(k) Clearance of the SoundBite™ Crossing System – Peripheral
MONTREAL – SoundBite Medical Solutions Inc. (SBMS)today announces it has received U.S. Food and Drug Administrati... |
| 09.01.2020 | adMare BioInnovations & Accel-Rx Unite to Advance the Canadian Life Sciences Sector | Vancouver, Canada: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), ann... |
| 18.11.2019 | adMare BioInnovations Appoints Dr. Mounia Azzi as Vice President, Program Development and Partnerships | Vancouver, BC and Montreal, QC: adMare BioInnovations, Canada’s Global Life Sciences Venture, is pleased to announce the appointment of Dr. Mounia Azzi as Vice President, Program Development and Partnerships. As a member of adMare’s senior ... |
| - | - | CDRD is a proud sponsor of the TAT11 International Symposium on targeted alpha therapy hosted by Canadian Nuclear Laboratories. We are excited to be co-hosting a panel discussion “The Renaissance of Radio Pharmaceuticals – A Commercial Pers... |
| - | - | Ottawa and Vancouver, Canada: CDRD, The Centre for Drug Research and Development will be honoured with the 2018 BIOTECanada Gold Leaf Ecosystem Builder Award at a special Global Biotech Week event tonight in Ottawa.
The award recognizes CDR... |
| - | - | Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national life sciences venture, is pleased to announce the appointment of Mr. Didier Leconte as a new Director of the organization.
Mr. Leconte is Vice-Preside... |
| - | - | Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national drug development and commercialization centre, is pleased to announce the appointment of Sacha Mann as an Entrepreneur-in-Residence.
Sacha Mann has a ... |
| - | - | An op/ed piece submitted to the Canadian Science Policy Centre. You can find the original article here: sciencepolicy.ca/news/budget-2018-platform-scale-and-focus-canadian-life-sciences.
By: Gordon C. McCauley
President & CEO
CDRD – The... |
| - | - | Vancouver, Canada: CDRD, Canada’s national life sciences venture, is pleased to announce the appointments of Ms. Wendy Hurlburt and Mr. William Charnetski as new Directors of the organization.
Wendy Hurlburt, an executive with more than 20 ... |
| - | - | CDRD, Canada’s national drug development and commercialization centre, is pleased to share that “ZW49” by Zymeworks is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate (ADC) platf... |
| - | - | Dr. Peter Bergqvist describes how some of his work contributed to a recent commercial outcome for TxCell (now Sangamo Therapeutics) with our academic partner Dr. Megan Levings at UBC.
The work has also been published here: https://insight.j... |
| - | - | Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national life sciences venture, is pleased to announce the first cohort of the CDRD Academy’s Executive Institute.
Earlier this year, CDRD and Pfizer Canada an... |
| - | Life Sciences & Health Technology Innovation Hub Takes Shape in Montreal | The NEOMED Innovation Centre will be expanded with the construction of a new innovation and commercialization complex specializing in life sciences and health technology
Montreal, Quebec – adMare BioInnovations held today the ground breakin... |
| - | NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound | Christine Lennon named President & CEO
IND Qualifying Toxicology Studies Initiated for NEO2734
Funding sought to fund:
Phase 1/2 Studies for NE02734
Preclinical Dual BET/SMARCA4 Discovery Program
Clinical Biomarker Program
Montreal, Que... |
| - | - | Vancouver, Canada: CDRD, Canada’s national drug development and commercialization centre, congratulates Dr. Alan Winter on being named British Columbia’s first Innovation Commissioner. The creation of this position is a strong indication of... |
| - | - | VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from t... |
| - | NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting | – An analgesic effect demonstrated –
– No increase in body temperature nor change in heat pain perception –
Montreal, October 30, 2017 – The NEOMED Institute announced today that it will present a poster on the Phase II data for its lead pr... |
| - | CDRD & NEOMED Institute Join Forces to Create a New Pan-Canadian Enterprise adMare BioInnovations | Vancouver, BC and Montreal, QC: Two successful Canadian innovation organizations, CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréa... |
| - | - | Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians
Declared a Global Health Priority by the World Health Org... |
| - | - | Vancouver, BC and Ottawa, ON: CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promi... |
| - | Hope on the horizon for hard-to-treat breast cancers | Montreal, Canada – The NEOMED Institute (NEOMED), CQDM, the Canadian Cancer Society (CCS), the Goodman Cancer Research Centre (GCRC) and the Lady Davis Institute (LDI) announced today a unique multi-party collaboration to develop new anti-c... |
| - | adMare Portfolio Company BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough | LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough... |
| - | New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration | Montreal, Canada and London, UK: The NEOMED Institute (NEOMED), GlaxoSmithKline Inc. (GSK), the Centre Hospitalier de l’Université de Montréal (CHUM) Research Centre and University College London (UCL) are pleased to announce that they have... |
| - | - | Vancouver, Canada: CDRD, Canada’s national life sciences venture, has been selected for a Science Co-op Employer Recognition Award by the University of British Columbia (UBC). In addition, two of CDRD’s employees : David Shin, Data Integrit... |
| - | - | In celebration of Global Biotech Week, CDRD and BIOTECanada invite you to a thought-provoking evening to experience the change unfolding in real time. Join futurist Dr. Juan Enriquez, noted author (As the Future Catches You), Harvard profes... |
| - | - | Translational research is a high-risk, iterative phase of the drug development pipeline that is critical in ensuring both a drug’s safety and efficacy. Key questions are answered about a potential drug in translational research: How quickly... |
| - | Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative | If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020. What is CARI?
CARI is a collaboration between The Centre ... |
| - | adMare Launches Abdera with AbCellera as a Founding Partner | adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company developing novel ne... |
| - | New life sciences company takes aim at obesity, toxic effects of overnutrition — NIMIUM Therapeutics launches in Montreal | A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases.
The company’s foundational technology is based on the cutting-edge research of the lab... |
| - | adMare Academy Announces New Executive Institute Cohort to Drive the Canadian Life Sciences Industry Forward | Vancouver, Canada: The adMare Academy is pleased to announce the latest Canadian life science leaders accepted into its Executive Institute — a one-of-a-kind national executive development program custom designed to ensure that the Canadian... |
| - | adMare BioInnovations Launches a New Acceleration Program for Quebec Emerging Companies | New program supported by the Quebec Government and the City of Montreal looks to scale-up the province’s most promising young life sciences companies.
Montreal, QC – June 29th, 2020: adMare BioInnovations (adMare) is pleased to announce the... |
| - | - | To exemplify the collaborative spirit and leadership needed to advance the Canadian health and biosciences sector, Canadian life sciences leaders – CDRD, LifeSciences BC, TRIUMF Innovations and BIOTECanada – are hosting an event today to bu... |
| - | - | Welcome to CDRD – Built for Success
Every day is a revolution in life science in this world – from new cutting-edge drug development technologies and processes to a changing global business model, the life sciences sector pushes the boundar... |
| - | Join Us on May 30th, for the Official Opening of adMare’s Montreal Innovation Centre Expansion & BIOQuébec’s 2022 AGA | adMare BioInnovations and BIOQuébec cordially invite you to join your fellow Quebec life sciences leaders for a very special evening to celebrate the official opening of adMare’s new facility. Special guests will be attending in support of ... |
| - | - | Vancouver, Canada: CDRD, Canada’s national drug development and commercialization centre, is pleased to announce the appointment of Dr. Brad Popovich as Chair of its Board of Directors, Mr. Douglas Wilkes as Vice-Chair, and Dr. Laurence Rul... |
| - | - | Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep.
Current therapies offer hypoglycemic treatment only once an episode occurs.
Zucara is working on the first treatment to p... |
| - | NEOMED Institute partners with McGill University to identify small molecule inhibitors of a novel oncology target: Cut-Like Homeobox 1 (CUX1) | Montreal, Quebec, Canada May 3rd, 2018 – The NEOMED Institute announced today that it has entered into a development collaboration with McGill University. Dr. Kemal Payza, Senior Project Director at NEOMED Institute will collaborate with Dr... |
| - | - | Share |
| - | - | Vancouver, Canada – CDRD, Canada’s national life sciences venture, is pleased to announce an increased commitment to Sitka Biopharma with a $1.2M investment. This new investment will enable Sitka and its partner Cancer Research UK (CRUK) to... |
| - | - | Toronto, Canada: The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, and Pfizer Canada today announced the launch of the CDRD Executive Institute under the umbrella of The CD... |
| - | adMare BioInnovations Appoints Dr. Youssef Bennani as Venture Partner | Vancouver, BC and Montreal, QC: adMare BioInnovations, a pan-Canadian life sciences enterprise with global reach, is pleased to announce the appointment of Dr. Youssef Bennani as a Venture Partner. adMare BioInnovations was recently created... |
| - | - | Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from... |
| - | - | Please add as a news item to CDRD website
Spring/Summer 2018 Communique
As Canada’s national life sciences venture, CDRD powers the country’s industry by creating and growing companies of scale – while training the scientific and business t... |
| - | Ingenuity in Canada’s life-sciences sector key piece in responding to global COVID-19 fight | While celebrating the heroism of those on the front lines fighting this pandemic, we have reached the point where we can consider life after COVID-19. Or perhaps we should say life with COVID-19. It will be with us for a while, and we will ... |
| - | - | CDRD – The Centre for Drug Research and Development, Canada’s national drug development and commercialization centre, is pleased to announce the appointment of Dr. Lana Janes as an Entrepreneur-in-Residence.
As a life sciences industry exec... |
| - | - | Collaboration to utilize Schrodinger’s advanced computation platform technology to accelerate discovery of immuno-oncology and other cancer biologics
NEW YORK, NY & VANCOUVER, CANADA – Schrödinger, Inc., a privately-held company dedicat... |
